Approval · Notice of Compliance 29219 · 2022
EVUSHELD: Notice of Compliance 29219
Issued October 18, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29219
- Date
- October 18, 2022
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication : EVUSHELD (tixagevimab and cilgavimab) is indicated for the treatment of mild to moderate COVID-19 in adults and adolescents (>12 years of age weighing at least 40 kg)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EVUSHELD | Not yet assigned | — |
Medicinal ingredients
- TIXAGEVIMAB 150 MG per 1.5ML
- CILGAVIMAB 150 MG per 1.5ML